Overview

We aim to develop novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly in the areas of biosurgical and passive immunotherapy products. We are utilizing our proprietary protein purification technology, innovative development capabilities, and manufacturing know-how to develop these product lines.

Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market.

Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.